| Liu, Ping |
NCT05064748: Phase IV Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Psoriasis in Adults |
|
|
| Recruiting | 4 | 2000 | RoW | Benvitimod | Peking University People's Hospital, Zhonghao Pharmaceutical | Psoriasis | 03/24 | 09/24 | | |
COPEC, NCT04922853: Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer |
|
|
| Recruiting | 3 | 554 | RoW | Capox chemotherapy | West China Hospital, The Third People's Hospital of Chengdu, Chengdu Fifth People's Hospital, Peking Union Medical College, Beijing Cancer Hospital, Sun Yat-sen University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Yunnan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Affiliated Hospital Of Guizhou Medical University, Sichuan Provincial People's Hospital, Nanchong Central Hospital, Dazhou Central Hospital, Leshan People's Hospital, GeneCast Biotechnology Co., Ltd. | Rectal Cancer, Neoadjuvant Chemotherapy | 12/24 | 12/26 | | |
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder |
|
|
| Completed | 3 | 206 | RoW | Daridorexant, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Insomnia Disorder | 04/24 | 05/24 | | |
NCT06347653: Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL) |
|
|
| Recruiting | 2 | 54 | RoW | linperlisib combined with CHOP regimen | Peking University | Nodal T-follicular Helper Cell Lymphoma | 01/27 | 01/30 | | |
NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) |
|
|
| Recruiting | 2 | 64 | RoW | LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection | Lyvgen Biopharma Holdings Limited | Head and Neck Squamous Cell Carcinoma | 10/27 | 10/27 | | |
NCT04509466: Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL |
|
|
| Terminated | 1/2 | 41 | RoW | Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 1, Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 2 (treatment-naïve patients), Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 2 (relapsed or refractory patients) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Extranodal NK/T-cell Lymphoma, Nasal Type | 01/22 | 01/22 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT04711980: Post-marketing Evaluation of Mudan Granule Intervention on Type 2 Diabetic Peripheral Neuropathy |
|
|
| Not yet recruiting | 1 | 402 | RoW | Mudan granule, Mudan particle, Placebo, Placebos | Fengmei Lian, Peking Union Medical College Hospital, Beijing Hospital, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Affiliated Hospital of Qingdao University, Chengdu University of Traditional Chinese Medicine, The Fourth People's Hospital of Chongqing, Zhengzhou Yihe Hospital Affiliated to Henan University, Zhu Xianyi Memorial Hospital of Tianjin Medical University, The Third Hospital of Xi'an, Huashan Hospital, Gansu Provincial People's Hospital, Shenzhen Hospital of Guangzhou University of Traditional Chinese Medicine, Affiliated Hospital of Changchun University of Chinese Medicine | Diabetic Peripheral Neuropathy Type 2 | 02/22 | 09/22 | | |
NCT04461431: Clinical Study of Posterolateral Structure of Knee Joint Under Arthroscopy |
|
|
| Recruiting | N/A | 20 | RoW | Arthroscopic anatomical reconstruction of the posterolateral structure of the knee | Peking University Third Hospital | the Posterolateral Structure of the Knee Joint, Arthroscopy, Anatomical Reconstruction | 07/20 | 01/22 | | |
NCT05214651: A Clinical Research on Repair of Massive-large Rotator Cuff Tears |
|
|
| Recruiting | N/A | 52 | RoW | novel double row, suture bridge double row | Peking University Third Hospital | Rotator Cuff Tears | 05/26 | 05/26 | | |
NCT05383521: Safety and Efficacy of Two Oral Tinidazole Regimens for Refractory Trichomonas Vaginitis |
|
|
| Not yet recruiting | N/A | 20 | RoW | Tinidazole 56, Tinidazole M56, Tinidazole 42, Tinidazole M42 | Shangrong Fan | Trichomonas Vaginitis | 12/25 | 12/25 | | |
NCT04456881: Arthroscopic Clinical Study of Double Bundle Anatomical Reconstruction of Medial Patellofemoral Ligament |
|
|
| Recruiting | N/A | 30 | RoW | Patients with patellar dislocation undergo patellar femoral medial reconstruction | Peking University Third Hospital | Recurrent Patellar Dislocation | 02/24 | 05/24 | | |
NCT05968001: Obinutuzumab in Chinese Real-world Patients With iNHL |
|
|
| Not yet recruiting | N/A | 400 | RoW | Obinutuzumab | Affiliated Hospital of Nantong University | Lymphomas Non-Hodgkin's B-Cell | 12/24 | 07/26 | | |
NCT05409482: A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | | Meng Chao Hepatobiliary Hospital of Fujian Medical University, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Hepatocellular Carcinoma | 03/26 | 03/26 | | |
| Recruiting | N/A | 10000 | RoW | No intervention | Peking University People's Hospital | Dermatitis, Atopic | 10/24 | 10/24 | | |
| Zhou, Zhiguang |
NCT05005741: The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity. |
|
|
| Recruiting | 4 | 120 | RoW | Beinaglutide, GLP-1 receptor agonist, Dulaglutide, Trulicity | Second Xiangya Hospital of Central South University, Guangdong Provincial People's Hospital, First Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Henan University of Science and Technology | Diabetes Mellitus, Type 2, Overweight or Obesity | 12/23 | 12/23 | | |
PB119, NCT04504370: Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects |
|
|
| Completed | 3 | 273 | RoW | GLP-1 receptor agonist, Placebo, PB-119 Placebo | PegBio Co., Ltd. | Type 2 Diabetes Mellitus (T2DM) | 03/22 | 11/22 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
HRS9531-302, NCT06650007: the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone |
|
|
| Recruiting | 3 | 210 | RoW | HRS9531 Injection, HRS9531 Placebo Injection | Fujian Shengdi Pharmaceutical Co., Ltd. | Diabetes Mellitus, Type 2 | 07/26 | 07/26 | | |
| Recruiting | 3 | 344 | RoW | Insulin degludec injection, Tresiba® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Type 2 Diabetes | 12/25 | 12/25 | | |
NCT02932826: Safety Study and Therapeutic Effects of Umbilical Cord Blood Treg on Autoimmune Diabetes |
|
|
| Recruiting | 1/2 | 40 | RoW | Umbilical Cord Blood Regulatory T cells Therapy, Insulin | Second Xiangya Hospital of Central South University | Diabetes Mellitus, Type 1 | 06/25 | 11/25 | | |
NCT03011021: Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes |
|
|
| Recruiting | 1/2 | 40 | RoW | Liraglutide, UCB-Treg, Insulin | Second Xiangya Hospital of Central South University | Type1 Diabetes Mellitus, Autoimmune Diabetes | 06/25 | 06/25 | | |
NCT04435158: A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients |
|
|
| Completed | 1 | 107 | RoW | SHR-1222, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Osteoporosis | 07/22 | 07/22 | | |
NCT04096794: Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research |
|
|
| Recruiting | N/A | 500 | RoW | | Second Xiangya Hospital of Central South University | Type 1 Diabetes Mellitus | 09/27 | 09/27 | | |
NCT05498974: China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes |
|
|
| Recruiting | N/A | 20000 | RoW | Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center | Second Xiangya Hospital of Central South University | Type1diabetes, Diabetes | 12/35 | 12/35 | | |
| Li, Xia |
NCT04146155: Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease |
|
|
| Recruiting | 4 | 200 | RoW | Liraglutide+standard-of-care treatment, Victoza, standard-of-care treatment | Second Affiliated Hospital, School of Medicine, Zhejiang University | Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus | 12/21 | 12/21 | | |
| Active, not recruiting | 4 | 800 | RoW | Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 06/25 | | |
TRAPP, NCT05811676: Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women with Placenta Previa |
|
|
| Recruiting | 3 | 1680 | RoW | Tranexamic acid, 0.9% sodium chloride | Guangzhou Medical University, Dongguan Maternal and Child Health Care Hospital, Foshan Women and Children Hospital, BoAi Hospital of Zhongshan, Women and Children's Hospital of Chongqing Medical University, Tianjin Central Hospital of Gynecology Obstetrics, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Urumqi Maternal and Child Health Care Hospital, Zhuhai Women and Children's Hospital, The First Affiliated Hospital of Zhengzhou University, Hunan Provincial Maternal and Child Health Care Hospital, Dalian women and children's medical group, Nanfang Hospital, Southern Medical University, Huadu District People's Hospital of Guangzhou, Northwest Women's and Children's Hospital, Xi'an, Shaanxi, First Affiliated Hospital, Sun Yat-Sen University, Shenzhen Maternity & Child Healthcare Hospital, Shenzhen Baoan Women's and Children's Hospital, Dongguan People's Hospital, First Affiliated Hospital of Xinjiang Medical University, Tongji Hospital, Peking Union Medical College, Peking University First Hospital, The First Affiliated Hospital of Guangzhou Medical University, Second Affiliated Hospital of Guangzhou Medical University, Fifth Affiliated Hospital of Guangzhou Medical University, Shijiazhuang Obstetrics and Gynecology Hospital | Hemorrhage, Postpartum, Placenta Previa | 02/25 | 04/25 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) |
|
|
| Recruiting | 2 | 64 | RoW | LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection | Lyvgen Biopharma Holdings Limited | Head and Neck Squamous Cell Carcinoma | 10/27 | 10/27 | | |
| Recruiting | 2 | 120 | RoW | TQH3906 capsules, Placebo of TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Plaque Psoriasis | 01/25 | 09/25 | | |
NCT04094740: Effect of Needle-free Jet Injection of Insulin on Glucose Control and Injection Feelings in Type 1 Diabetic Patients |
|
|
| Not yet recruiting | N/A | 60 | NA | Jet Injector without A Needle | Second Xiangya Hospital of Central South University | Type 1 Diabetes | 08/20 | 12/23 | | |
NCT04016987: Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes |
|
|
| Recruiting | N/A | 138 | RoW | Automated structured education intervention based on an app and artificial intelligence | Second Xiangya Hospital of Central South University | Type 1 Diabetes | 12/21 | 12/23 | | |
| Recruiting | N/A | 10254 | RoW | | Limeng Chen | Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder | 12/24 | 12/24 | | |
| Terminated | N/A | 11 | RoW | Surpass Streamline Flow Diverter System | Stryker Neurovascular, Stryker (Beijing) Healthcare Products Co., Ltd | Aneurysm, Intracranial | 09/23 | 09/23 | | |
NCT06496412: Safety and Efficacy of Fecal Microbiota Transplantation on Cognitive Function in T1DM |
|
|
| Recruiting | N/A | 40 | RoW | fecal microbiota transplantation, Placebo | Second Xiangya Hospital of Central South University | Type 1 Diabetes | 12/26 | 12/27 | | |
NCT06423547: Risk Warning Model of Postoperative Delirium and Long-term Cognitive Dysfunction in Elderly Patients |
|
|
| Not yet recruiting | N/A | 10000 | NA | no intervention | Xuanwu Hospital, Beijing, Chongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences | Postoperative Delirium, Postoperative Neurocognitive Disorder, Surgery | 12/27 | 12/27 | | |
NCT05359796: Clinical Characteristics of People With Long-term Type 1 Diabetes |
|
|
| Recruiting | N/A | 400 | RoW | Chronic hyperglycemia, Residual islet function, Genetic variation, Dietary constitutes, Microbiome composition and function, Metabolome composition, Composition of peripheral blood immune cells | Second Xiangya Hospital of Central South University | Type 1 Diabetes | 12/25 | 12/27 | | |
NCT05498974: China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes |
|
|
| Recruiting | N/A | 20000 | RoW | Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center | Second Xiangya Hospital of Central South University | Type1diabetes, Diabetes | 12/35 | 12/35 | | |
| Yao, Hongliang |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NCT03273920: Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer |
|
|
| Not yet recruiting | N/A | 1110 | RoW | Robotic distal gastrectomy with D2 nodal dissection, Laparoscopic distal gastrectomy with D2 nodal dissection | Southwest Hospital, China, Chinese PLA General Hospital, West China Hospital, Xijing Hospital of Digestive Diseases, Nanjing PLA General Hospital, Peking University Cancer Hospital & Institute, Qingdao University, Fujian Medical University Union Hospital, Central South University, The First Affiliated Hospital of Nanchang University, Sun Yat-sen University, Wuhan Union Hospital, China, Jilin Provincial Tumor Hospital, Lanzhou General Hospital of PLA | Gastric Cancer | 09/19 | 09/22 | | |
NOTR, NCT04230772: Clinical Outcomes of NOSES Versus Traditional Robotic-assisted Surgery for Patients With Colorectal Cancer |
|
|
| Recruiting | N/A | 550 | RoW | Natural Orifice Specimen Extraction Surgery, Traditional Robotic-assisted Surgery | Taiyuan Li | Colorectal Neoplasms, Neoplasms Malignant, Complication of Surgical Procedure, Robotic Surgical Procedures, Natural Orifice Specimen Extraction Surgery | 12/21 | 12/22 | | |
NCT05468944: Robotic Transanal Specimen Extraction Surgery Versus Robotic Transabdominal Incision Specimen Extraction Surgery for Patients With Rectal Cancer: A Multicenter Randomized Controlled Trial |
|
|
| Not yet recruiting | N/A | 556 | RoW | Transanal specimen extraction robotic surgery, Transabdominal specimen extraction robotic surgery | Taiyuan Li | Rectal Neoplasms, Robotic Surgery, Natural Orifice Specimen Extraction Surgery | 12/25 | 12/25 | | |
| Jiang, Yongfang |
NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. |
|
|
| Completed | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 10/24 | 10/24 | | |
NCT05905172: Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis |
|
|
| Recruiting | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 06/28 | 10/28 | | |
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) |
|
|
| Recruiting | 2 | 120 | RoW | TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-alcoholic Steatohepatitis | 12/26 | 12/27 | | |
TQA3605-II-01, NCT06644417: Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection |
|
|
| Recruiting | 2 | 120 | RoW | TQA3605 tablets plus NAs, TQA3605 Placebo plus NAs | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HBV Infection With LLV | 04/26 | 08/26 | | |
| Recruiting | 2 | 116 | RoW | Placebo, TQA3334 Tablet, Nucleoside (acid) analogs (NAs) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Hepatitis B | 12/25 | 06/26 | | |
NCT05937178: Real-world Study Optimizing Nucleotide-analogues |
|
|
| Recruiting | N/A | 20000 | RoW | ETV/TAF/TDF/TMF/IFN, ETV/TAF/TDF/TMF | Huashan Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, Beijing YouAn Hospital, Peking University People's Hospital, Peking University First Hospital, Xiamen Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Fujian Medical University, LanZhou University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Hainan General Hospital, Hebei Medical University Third Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Henan Provincial People's Hospital, The Second Affiliated Hospital of Harbin Medical University, Tongji Hospital, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, the Second Hospital of Nangjing, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital of Nanchang University, Shengjing Hospital, Qingdao Sixth People's Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University, The Second Hospital of Shandong University, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, West China Hospital, Tianjin Second People's Hospital, First Affiliated Hospital of Xinjiang Medical University, The First People's Hospital of Yunnan, Shulan (Hangzhou) Hospital, Zhejiang University, Southwest Hospital, China, The Second Affiliated Hospital of Chongqing Medical University, Sichuan Provincial People's Hospital | Hepatitis B, Chronic | 01/29 | 01/29 | | |
| Zhenfei, Fang |
NCT06211595: Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy |
|
|
| Active, not recruiting | N/A | 10 | RoW | DragonFire Transcatheter Myocardial Radiofrequency Ablation System | Hangzhou Valgen Medtech Co., Ltd | Obstructive Hypertrophic Cardiomyopathy | 12/23 | 11/24 | | |
NCT03601039: Safety and Efficacy Study of Absnow Absorbable ASD Closure System For Treating ASD Patients |
|
|
| Recruiting | N/A | 144 | RoW | Absnow Absorbable ASD Closure System | Lifetech Scientific (Shenzhen) Co., Ltd. | Heart Septal Defects, Atrial, Atrial Septal Defect | 03/24 | 06/24 | | |
| Cui, Yajuan |
NCT05334823: A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents |
|
|
| Recruiting | 2 | 100 | RoW | pCAR-19B cells | Chongqing Precision Biotech Co., Ltd | Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia | 12/24 | 07/25 | | |
| Shen, Tian |
NCT03791827: Multicenter Registry of Pediatric Lupus Nephritis in China |
|
|
| Recruiting | N/A | 1200 | RoW | Corticosteroid, Steroid, Prednisone, Methylprednisone, Prednisolone, Hydroxychloroquine, Cyclophosphamide, Mycophenolate Mofetil, Azathioprine, Tacrolimus, Cyclosporine A, Rituximab, anti-CD20 antibody | Xiqiang Dang, The Children's Hospital Affiliated to Suzhou University, Shandong Provincial Hospital, Guizhou Provincial People's Hospital, LanZhou University, The First Affiliated Hospital of Inner Mongolia Medical College, People's Hospital of Zhangjiajie, Puyang Oilfield General Hospital, The First Affiliated Hospital of Anhui Medical University, Guizhou Maternal and Child Health Care Hospital, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Shenzhen Children's Hospital, The Second Affiliated Hospital of Harbin Medical University, Yichang Central People's Hospital, Xian Children's Hospital, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science & Technology, The First People's Hospital of Yunnan, The First Affiliated Hospital of Xiamen University, The First Affiliated Hospital of Xinxiang Medical College, Shanxi Provincial Maternity and Children's Hospital, Liaocheng People's Hospital, Fujian Provincial Hospital, First Affiliated Hospital of Guangxi Medical University, Second Hospital of Lanzhou University, Guangzhou First People's Hospital, The Second Hospital of Shandong University, Children's Hospital of Hebei Province, Beijing Children's Hospital, Zhengzhou Children's Hospital, The Children's Hospital of Chongqing Medical University, Wuxi Children's Hospital, The Children's Hospital of Fudan University, Shanghai Children's Medical Center, Qilu Children's Hospital of Shandong University | Lupus Nephritis, Children, Steroid, Immunosuppressive Treatment | 11/23 | 11/24 | | |
| Peng, Hongling |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 06/25 | 01/28 | | |
NCT04453345: TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL |
|
|
| Recruiting | 2/3 | 42 | RoW | thalidomide + prednisone + methotrexate, TPM regimen | Institute of Hematology & Blood Diseases Hospital, The First Affiliated Hospital of Nanchang University, First Affiliated Hospital of Guangxi Medical University, Henan Cancer Hospital, First Hospital of Jilin University, Central South University, Tianjin First Central Hospital | T-LGL Leukemia, Clpd-Nk | 05/23 | 05/25 | | |
ICP-CL-01203, NCT06378138: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2/3 | 226 | RoW | ICP-248, Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematologic Malignancies | 11/30 | 07/31 | | |
NCT05334823: A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents |
|
|
| Recruiting | 2 | 100 | RoW | pCAR-19B cells | Chongqing Precision Biotech Co., Ltd | Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia | 12/24 | 07/25 | | |
| Not yet recruiting | 2 | 30 | RoW | R-EPOCH in Combination With Ibrutinib | Institute of Hematology & Blood Diseases Hospital, Xian-Janssen Pharmaceutical Ltd. | Richter Transformation | 08/24 | 08/25 | | |
NCT04808570: A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Terminated | 1/2 | 23 | RoW | TQ-B3525 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 11/23 | 11/23 | | |
| Pan, Jin |
NCT05334823: A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents |
|
|
| Recruiting | 2 | 100 | RoW | pCAR-19B cells | Chongqing Precision Biotech Co., Ltd | Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia | 12/24 | 07/25 | | |
| Li, Ruijuan |
NCT05334823: A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents |
|
|
| Recruiting | 2 | 100 | RoW | pCAR-19B cells | Chongqing Precision Biotech Co., Ltd | Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia | 12/24 | 07/25 | | |
| Xiao, Rong |
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 330 | RoW | SHR0302, Placebo | Reistone Biopharma Company Limited | Alopecia Areata | 10/23 | 02/24 | | |
NCT06521255: Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 244 | RoW | Tafasitamab, Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | DLBCL | 09/28 | 12/29 | | |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 747 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 08/25 | 10/25 | | |
NCT06552520: To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 500 | RoW | TQH2722 injection, Placebo of TQH2722 injection | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Atopic Dermatitis | 10/25 | 06/26 | | |
| Recruiting | 3 | 189 | RoW | Roflumilast Cream 0.3%, Zoryve, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Plaque Psoriasis | 06/25 | 07/25 | | |
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 3 | 552 | RoW | ICP-332 Tablets, ICP-332 Placebo Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Atopic Dermatitis | 11/26 | 12/26 | | |
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis |
|
|
| Recruiting | 3 | 351 | RoW | Roflumilast Cream 0.15%, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Atopic Dermatitis (AD) | 08/25 | 08/25 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
MARBLE-23, NCT04717310: Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis |
|
|
| Active, not recruiting | 2/3 | 645 | RoW | SHR0302 Ointment, SHR0302 Ointment 2%, SHR0302 Ointment 1%, SHR0302 Ointment 0.5%, Vehicle, Placebo | Reistone Biopharma Company Limited | Atopic Dermatitis | 09/23 | 07/24 | | |
NCT05531682: A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Completed | 2 | 160 | RoW | Placebo, HB0017, HB0017 dosing regimens | Huabo Biopharm Co., Ltd. | Plaque Psoriasis | 05/23 | 01/24 | | |
NCT06077331: A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 120 | RoW | HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched placebo tablets | Hansoh BioMedical R&D Company | Psoriasis | 07/24 | 08/24 | | |
NCT06149260: Subcutaneous Semaglutide in Systemic Scleroderma |
|
|
| Recruiting | 1 | 10 | RoW | Semaglutide Pen Injector | Second Xiangya Hospital of Central South University | Scleroderma, Systemic, Fibrosis, Semaglutide | 08/24 | 12/24 | | |
| Lu, Jianyun |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT05975268: A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 747 | RoW | JS005 (recombinant humanized monoclonal antibody against IL-17A) | Shanghai Junshi Bioscience Co., Ltd. | Moderate to Severe Chronic Plaque Psoriasis | 08/25 | 10/25 | | |
NCT06552520: To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 500 | RoW | TQH2722 injection, Placebo of TQH2722 injection | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Atopic Dermatitis | 10/25 | 06/26 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period |
|
|
| Active, not recruiting | 3 | 1108 | Europe, Canada, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 12/24 | 11/25 | | |
NCT05531682: A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Completed | 2 | 160 | RoW | Placebo, HB0017, HB0017 dosing regimens | Huabo Biopharm Co., Ltd. | Plaque Psoriasis | 05/23 | 01/24 | | |
NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 160 | RoW | TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Atopic Dermatitis | 03/24 | 03/24 | | |
NCT06109818: Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Recruiting | 2 | 129 | RoW | ICP-488 Tablets, ICP-488 Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Moderate to Severe Plaque Psoriasis | 10/24 | 11/24 | | |
| Recruiting | 2 | 120 | RoW | TQH3906 capsules, Placebo of TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Plaque Psoriasis | 01/25 | 09/25 | | |
| Yi, Wenjun |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
HEROIC, NCT06551220: Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns |
|
|
| Recruiting | N/A | 800 | RoW | Trastuzumab Deruxtecan | Sun Yat-sen University | Metastatic Breast Cancer | 01/25 | 01/25 | | |
| Xiao, Shuiyuan |
NCT06366373: Reducing Stigma Through a Mental Health Art Exhibition and Its Printed Brochure |
|
|
| Recruiting | N/A | 360 | RoW | A mental health art exhibition, printed or online education materials | Hunan University, Central South University, Qixi Charity | Mental Health Issue | 05/25 | 05/25 | | |
